Type 2 Diabetes and Testosterone Therapy

Type 2 Diabetes and Testosterone Therapy

A third of men with type 2 diabetes (T2DM) have hypogonadotrophic hypogonadism (HH) and associated increased risk of cardiovascular and all-cause mortality. Men with HH are at increased risk of developing incident T2DM. We conducted MEDLINE, EMBASE, and COCHRANE reviews on T2DM, HH, testosterone def...

Full description

Bibliographic Details
Main Author:	Geoffrey Hackett
Format:	Article
Language:	English
Published:	Korean Society for Sexual Medicine and Andrology 2019-01-01
Series:	The World Journal of Men's Health
Subjects:	Cardiovascular diseases Diabetes mellitus type 2 Hypogonadism Major adverse coronary events Testosterone deficiency

Similar Items

Long-Term Testosterone Therapy in Type 2 Diabetes Is Associated with Decreasing Waist Circumference and Improving Erectile Function
by: Geoffrey Hackett, et al.
Published: (2020-01-01)

Low Serum Testosterone Concentrations in Hospitalized Men with Poorly Controlled Type 2 Diabetes
by: Kyung-Soo Kim, et al.
Published: (2014-12-01)

Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol
by: Vittoria Russo, et al.
Published: (2021-03-01)

The prevalence of hypogonadism in men with type 2 diabetes mellitus in clinical practice
by: Galina A. Melnichenko, et al.
Published: (2019-06-01)

Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
by: Xiang Cai, et al.
Published: (2014-02-01)

Controversies in testosterone replacement therapy: testosterone and cardiovascular disease
by: Kathleen Hwang, et al.
Published: (2015-04-01)

Guidelines for the diagnosis and treatment of testosterone deficiency (hypogonadism) in male patients with diabetes mellitus (Draft)
by: Galina Afanas'evna Melnichenko, et al.
Published: (2017-06-01)

Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review
by: Yeo S, et al.
Published: (2021-01-01)

Prevalence of hypogonadism in male Type 2 diabetes mellitus patients with and without coronary artery disease
by: S V Madhu, et al.
Published: (2017-01-01)

Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
by: Jonathan Clavell-Hernández, et al.
Published: (2018-05-01)

The prevalence and associations of low testosterone levels and erectile dysfunction in a male diabetic urban population
by: Kemp, Tanja
Published: (2015)

Serum testosterone in males with newly diagnosed type 2 diabetes mellitus and microvascular complications
by: S. Bajaj, et al.
Published: (2016-02-01)

A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus
by: Pankaj Kumar Agarwal, et al.
Published: (2017-01-01)

Basal hyperinsulinemia beyond a threshold predicts major adverse cardiac events at 1 year after coronary angiogram in type 2 diabetes mellitus: a retrospective cohort study
by: Mukund Srinivasan, et al.
Published: (2017-05-01)

Animal Models of Diabetes-Related Male Hypogonadism
by: Anastasia Dimakopoulou, et al.
Published: (2019-09-01)

Clinicopathologic assessment of hypogonadism in men with type 2 diabetes mellitus
by: Theophilus E Ugwu, et al.
Published: (2016-01-01)

Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
by: Abdulmaged Traish
Published: (2016-11-01)

Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus
by: Liyao Fu, et al.
Published: (2021-10-01)

Lower circulating kisspeptin and primary hypogonadism in men with type 2 diabetes
by: Henry Asare‐Anane, et al.
Published: (2019-07-01)

The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China
by: Zheng Qin, et al.
Published: (2020-02-01)

Waist circumference is associated with major adverse cardiovascular events in male but not female patients with type-2 diabetes mellitus
by: Zhenhua Xing, et al.
Published: (2020-03-01)

Late-onset hypogonadism in men with type 2 diabetes mellitus and its role in the development of cardiovascular diseases (literature review)
by: E.V. Luchytskyy, et al.
Published: (2020-09-01)

Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting
by: Kassaian Seyed, et al.
Published: (2012-07-01)

The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism
by: Yu Seob Shin, et al.
Published: (2019-02-01)

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study
by: Haider A, et al.
Published: (2016-06-01)

Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
by: Daniel A Shoskes, et al.
Published: (2015-12-01)

Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality
by: Kevin M. Pantalone, et al.
Published: (2019-03-01)

The Role Of Elevated NT-ProbNP And Albuminuria As Cardio-Vascular Risk Factors In Type 2 Diabetes Mellitus Patients After Acute Coronary Syndrome
by: Trutz Johann, et al.
Published: (2015-06-01)

HYPOANDROGEN CONDITION AND CARDIOVASCULAR DISEASES: ACTUAL QUESTIONS OF COMORBIDITY IN CLINICAL PRACTICE
by: G. G. Sharvadze, et al.
Published: (2016-01-01)

EFFECT OF TESTOSTERONE REPLACEMENT THERAPY ON QUALITY OF LIFE OF TYPE 2 DIABETES PATIENTS AND ANDROGEN DEFICIENCY
by: V. N. Vasilkova, et al.
Published: (2016-03-01)

Endogenous testosterone and mortality risk
by: Emily J Meyer, et al.
Published: (2018-01-01)

UGT2B17 genotype and the pharmacokinetic serum profile of Testosterone during substitution therapy with Testosterone Undecanoate. A retrospective experience from 207 men with hypogonadism.
by: Anne Kirstine eBang, et al.
Published: (2013-07-01)

Impact of obstructive sleep apnea complicated with type 2 diabetes on long-term cardiovascular risks and all-cause mortality in elderly patients
by: Xiaofeng Su, et al.
Published: (2021-09-01)

Are women with type 2 diabetes mellitus more susceptible to cardiovascular complications following coronary angioplasty?: a meta-analysis
by: Pravesh Kumar Bundhun, et al.
Published: (2017-07-01)

Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia
by: Katherine Lang Rotker, et al.
Published: (2018-01-01)

Overselling hysteria, dangerously: the media coverage of testosterone therapy in men
by: Vance, Jay
Published: (2016)

Evolution of Guidelines for Testosterone Replacement Therapy
by: Hyun Jun Park, et al.
Published: (2019-03-01)

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond
by: Elif A Oral
Published: (2016-09-01)

Testosterone replacement therapy and cardiovascular events
by: Alp Burak Çatakoğlu, et al.
Published: (2017-10-01)

Prognostic impact of the atherogenic index of plasma in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention
by: Xiaoteng Ma, et al.
Published: (2020-11-01)